BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study.
about
Main roads to melanomaActivating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.Epidermal growth factor receptor inhibits colitis-associated cancer in micePlatelet-mimicry of cancer cells: epiphenomenon with clinical significance.Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia.High- and low-penetrance cutaneous melanoma susceptibility genes.Association between functional polymorphisms in genes involved in the MAPK signaling pathways and cutaneous melanoma riskBRAF(E600) in benign and malignant human tumours.Oncogenic BRAF-Mediated Melanoma Cell Invasion.Understanding spitzoid tumours: new insights from molecular pathology.Issues affecting molecular staging in the management of patients with melanomaBRAF kinase in melanoma development and progression.Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma.Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.Role of salvage esophagectomy after definitive chemoradiotherapy.Genetics and genomics of melanoma.Plasma cytokine and P-selectin levels in advanced malignancy: prognostic value and impact of low-molecular weight heparin administration.BRAF mutations in an Italian cohort of thyroid cancers.The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer.Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma
P2860
Q21245465-2B372611-A13D-45A5-AF6C-F0F68B08FC0AQ35033377-F0091466-CB11-4431-8FF6-892B5E61AE08Q36129106-85A69FE7-BD89-4E42-8AEF-843D0B47292FQ36247006-C5C34724-176D-47C0-A8F6-8A872AE0DB59Q36346491-3AC9ED1F-E347-4C74-92B0-E0D6B2B7408CQ36499211-5A2E6014-4D2A-4383-8E32-B91999A0F06AQ36740729-41D68D99-C0C7-4A99-B576-C22963D6B7FAQ36921234-B82E3CB1-91F7-4005-8795-41E6CC549DB9Q36957578-E7712D5E-14B7-46AA-B1F4-D4F9BEFBB5DCQ36960647-3C201171-4B57-4A18-A3F2-8D1EBAAFF670Q36990701-9E8C1D00-9D78-415B-9BDD-A77ED787DE70Q37086193-B5BF08C6-D503-4DE4-B36C-E41D6EB34249Q37152975-25B046E8-8A6B-4157-9344-E6A75C6B4272Q37340755-9422A2AE-27B4-4E48-8F35-6412FA861028Q37392031-D5C74B07-3080-4351-B681-BDA5C5B2FF2CQ37409032-D28B98D8-7BDF-4420-970B-E339BDD94F9AQ47365807-4E273F41-EBA9-436B-B261-2B4515BF38C4Q53366519-4034328D-0F21-46B2-8C0D-2943B8C02AC2Q53660179-40D557FD-BFEA-4492-B671-8C64CF031814Q57781575-B3089480-C28B-4FD4-A595-C2966A848881
P2860
BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
BRAF gene is somatically mutat ...... ian Melanoma Intergroup Study.
@en
BRAF gene is somatically mutat ...... ian Melanoma Intergroup Study.
@nl
type
label
BRAF gene is somatically mutat ...... ian Melanoma Intergroup Study.
@en
BRAF gene is somatically mutat ...... ian Melanoma Intergroup Study.
@nl
prefLabel
BRAF gene is somatically mutat ...... ian Melanoma Intergroup Study.
@en
BRAF gene is somatically mutat ...... ian Melanoma Intergroup Study.
@nl
P2093
P50
P356
P1476
BRAF gene is somatically mutat ...... ian Melanoma Intergroup Study.
@en
P2093
Amelia Lissia
Annangela Carboni
Antonella Manca
Antonio Cossu
Carla Rozzo
Daniele Castiglia
Elisabetta Petretto
Francesco Tanda
Giovanna Bianchi-Scarrà
Italian Melanoma Intergroup Study
P304
P356
10.1200/JCO.2004.07.112
P407
P577
2004-01-01T00:00:00Z